Eli Lilly is posting strong results, and that should continue. The drugmaker is dominating in its core therapeutic area. Lilly has several exciting pipeline candidates. Although some believe the stock ...
Eli Lilly and Novo Nordisk dominate the weight loss drug market. Both companies have generated significant growth thanks to these drugs over the past few years. Novo was first to market with ...
Eli Lilly 's fourth-quarter results blew past Wall Street estimates on Wednesday, as key GLP-1 drugs, Mounjaro for diabetes and Zepbound to treat obesity, grew triple-digits — and there's still plenty ...
Eli Lilly (LLY) Q4 revenue jumped 43% to $19.3B. Mounjaro sales surged 110% to $7.4B. Novo Nordisk (NVO) expects sales to decline 5% to 13% in 2026 due to pricing pressures and patent losses. Lilly’s ...
Eli Lilly (LLY) reported Q4 EPS of $7.54 versus $6.67 expected. Eli Lilly projected 2026 revenue of $80-83B. Eli Lilly’s Mounjaro revenue surged 110% to $7.4B in Q4. Zepbound revenue jumped 123% to $4 ...
Feb 12 (Reuters) - Eli Lilly (LLY.N), opens new tab had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday, ahead of an expected decision ...
FILE PHOTO: A drone view shows the Eli Lilly logo on one of the company’s offices in San Diego, California, U.S., November 21, 2025. REUTERS/Mike Blake/File Photo Feb 12 (Reuters) - Eli Lilly had $1.5 ...
Eli Tomac was involved in a first-turn crash in Round 5 of the SuperMotocross World Championship at State Farm Stadium in Glendale, Arizona, and was slow to rise. After remounting his KTM in 22nd, he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results